G. Bouvenot

Adherence to treatment of osteoporosis: a need for study (2007)

Lekkerkerker, F, Kanis, JA, Alsayed, N, Bouvenot, G, Burlet, N, Cahall, D, ...

Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to...

Adherence to treatment of osteoporosis: a need for study (2007)

LEKKERKERKER, F, KANIS, JA, ALSAYED, N, BOUVENOT, G, BURLET, N, CAHALL, D, ...

Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis (2005)

Altman, RD, Abadie, E, Avouac, B, Bouvenot, G, Branco, J, Bruyère, Olivier, ...

Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to joint surgery as a potential therapeutic failure outcome...

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach (2004)

Richy, F, Bruyère, Olivier, Ethgen, Olivier, Rabenda, Véronique, Bouvenot, G, Audran, M, ...

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. METHODS:...

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis (2004)

Abadie, Eric, Ethgen, Dominique, Avouac, Bernard, Bouvenot, G, Branco, J, Bruyère, Olivier, ...

Background: Recent innovations in the pharmaceutical drug discovery environment have generated new chemical entities with the potential to become disease modifying drugs for osteoarthritis (DMOAD's)....

Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain (2004)

DEVOGELAER, J, DREISER, R, ABADIE, E, AVOUAC, B, BOUVENOT, G, CARBONELL, A, ...

[Clinical practice guideline: medical and nonmedical therapeutic strategies for smoking cessation. Bit of therapeutic practice: management and current practice in smoking cessation] (2003)

Le Foll, B, Melihan-Cheinin, P, Rostoker, G, Ades, J, De Beaurepaire, R, ...

Do estrogens effectively prevent osteoporosis-related fractures? (2000)

REGINSTER, JY, BRUYERE, O, AUDRAN, M, AVOUAC, B, BODY, JJ, BOUVENOT, G, ...

Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. (1998)

LEMMEL, EM, REID, DM, NUKI, G, AVOUAC, B, BARDIN, T, BOUVENOT, G, ...

Recommendations for the registration of drugs used in the treatment of osteoarthritis. (1996)

DOUGADOS, M, DEVOGELAER, JP, ANNEFELDT, M, AVOUAC, B, BOUVENOT, G, COOPER, C, ...

Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. (1996)

COMPSTON, JE, AUDRAN, M, AVOUAC, B, BOUVENOT, G, DEVOGELAER, JP, EASTELL, R, ...

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. (1995)

REGINSTER, J, COMPSTON, J, JONES, E, Kaufman, Jean, AUDRAN, M, BOUVENOT, G, ...

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

Richy, F, Bruyere, O, Ethgen, O, Rabenda, V, Bouvenot, G, Audran, M, ...

Methods: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse...

Delivering generics without regulatory incentives?: Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names

Paraponaris, A., Verger, P., Desquins, B., Villani, P., Bouvenot, G., Rochaix, L., ...